Fulgent Genetics (FLGT) Expected to Announce Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) will likely be releasing its earnings data before the market opens on Friday, February 28th. Analysts expect Fulgent Genetics to post earnings of ($0.31) per share and revenue of $75.39 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Fulgent Genetics Price Performance

Shares of FLGT stock opened at $16.66 on Friday. Fulgent Genetics has a 1 year low of $15.99 and a 1 year high of $25.50. The company has a market cap of $509.66 million, a PE ratio of -3.02 and a beta of 1.39. The stock’s 50 day simple moving average is $17.74 and its two-hundred day simple moving average is $19.84.

Insiders Place Their Bets

In related news, CEO Ming Hsieh sold 2,227 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $18.26, for a total transaction of $40,665.02. Following the transaction, the chief executive officer now directly owns 703,711 shares in the company, valued at $12,849,762.86. The trade was a 0.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 3,413 shares of company stock worth $62,321. 31.76% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.